PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for patients with LDL elevation and without CHD, clinical trials results

cholestyramine versus placebo
LRC, 1984
cholestyramine 24 g daily
versus
placebo
asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia)double blind
Follow-up duration: 7.4 years
USA
clofibrate versus placebo
Cullen, 1974
clofibrate
versus
placebo

Follow-up duration: 2 years
WHO clofibrate, 1978
clofibrate 1.6 g daily
versus
olive oil
primary prevention, Hommes, de 30 à 59 ans double blind
Follow-up duration: 5.3 years
Scotland, Hungary, Czech Republic
colestipol versus placebo
Gundersen, 1976
colestipol 10g twice daily
versus
placebo
hypercholesterolemic patients double-blind
Follow-up duration: 0.8 years
Ruoff, 1978
colestipol
versus
placebo
hypercholesterolemic patients
Follow-up duration: 3.2 years
Ryan, 1974
colestipol15 g/day
versus
placebo
patients with hypercholesterolemia
Follow-up duration: 3.0 years
UCS (Dorr), 1978
colestipol hydrochloride 32 mg/dl
versus
placebo
Hommes et femmes, > 18 ans double blind
Follow-up duration: 1.9 years
diet versus usual diet
Finnish Mental Hospital (Miettinen), 1985
cholesterol-lowering diet (low in saturated fats and cholesterol and relatively high in polyunsaturated fats)
versus
usual diet
middle-aged institionalized women without CHDopen, blind assessment
Follow-up duration: 6.0 years
Finland
Goteborg, 1986
multifactorial intervention programme
versus
no intervention
men, 47-55 years old at entryopen
Follow-up duration: 10 years
Sweden
Hjermann, 1981
diet
versus
usual diet
healthy, normotensive men at high risk of coronary heart disease open
Follow-up duration: 6.5 years
Sweden
MRFIT, 1982
multifactor intervention program
versus
usual diet
high-risk men aged 35 to 57 yearsopen
Follow-up duration: 6.5 y
Veterans Ad. (Dayton), 1969
cholesterol lowering diet
versus
usual diet
men in domicilary care, age>55, with or without CHDdouble blind
Follow-up duration: 3.6 and 8 y
USA
WHO Collaborative, 1986
multifactorial prevention
versus
usual diet
middle-aged men open
Follow-up duration: 5.5 years
Belgium, Italy, Poland, UK
gemfibrozil versus placebo
Helsinki (HHS), 1987
gemfibrozil 1,2 g/d
versus
placebo
asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to 200 mg per deciliter [5.2 mmol per liter]double blind
Follow-up duration: 5 years
Finland
lovastatin versus placebo
AFCAPS/TexCAPS, 1998
lovastatin 20-40 mg/d
versus
placebo
men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levelsdouble blind
Follow-up duration: 5.2 years
USA
pravastatin versus placebo
WOSCOPS, 1995
pravastatine 40 mg daily
versus
placebo
men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL) double blind
Follow-up duration: 4.9 years
Scotland
probucol versus control
FATS Fukosawa (probucol), 2002
probucol 500 mg/day
versus
diet alone
asymptomatic patients with hypercholesterolemiaopen
Follow-up duration: 2 years
Japan

  Options


in first

in second

  Filter